MX2018011622A - Pirimidinas y sus variantes, y usos de las mismas. - Google Patents

Pirimidinas y sus variantes, y usos de las mismas.

Info

Publication number
MX2018011622A
MX2018011622A MX2018011622A MX2018011622A MX2018011622A MX 2018011622 A MX2018011622 A MX 2018011622A MX 2018011622 A MX2018011622 A MX 2018011622A MX 2018011622 A MX2018011622 A MX 2018011622A MX 2018011622 A MX2018011622 A MX 2018011622A
Authority
MX
Mexico
Prior art keywords
pyrimidines
variants
uses therefor
present disclosure
disclosure provides
Prior art date
Application number
MX2018011622A
Other languages
English (en)
Inventor
Charles Hawley Ronald
P Ford Anthony
Ibrahim Prabha
R Gever Joel
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of MX2018011622A publication Critical patent/MX2018011622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente descripción proporciona compuestos de pirimidina de la Formula 1 y sus usos, por ejemplo, para el tratamiento potencial de enfermedades asociadas con receptores purinérgicos P2X. En ciertos aspectos, la presente descripción proporciona antagonistas de P2X3 y/o P2X213 que son Útiles, por ejemplo, para el tratamiento potencial de Órganos viscerales, enfermedades, condiciones y trastornos cardiovasculares y relacionados con el dolor.
MX2018011622A 2016-03-25 2017-03-20 Pirimidinas y sus variantes, y usos de las mismas. MX2018011622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (1)

Publication Number Publication Date
MX2018011622A true MX2018011622A (es) 2019-03-28

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011622A MX2018011622A (es) 2016-03-25 2017-03-20 Pirimidinas y sus variantes, y usos de las mismas.

Country Status (12)

Country Link
US (2) US10662162B2 (es)
EP (1) EP3433258B1 (es)
JP (1) JP6902045B2 (es)
KR (1) KR102377805B1 (es)
CN (1) CN108779119B (es)
AU (1) AU2017237929B2 (es)
BR (1) BR112018069105A2 (es)
CA (1) CA3018180C (es)
MA (1) MA44489A (es)
MX (1) MX2018011622A (es)
RU (1) RU2760733C2 (es)
WO (1) WO2017165255A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968810B2 (ja) 2016-03-14 2021-11-17 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
CA3018180C (en) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
PT3555048T (pt) 2016-12-19 2021-09-29 Novartis Ag Novos derivados de ácidos picolínicos e uso dos mesmos como intermediários
CN110087654A (zh) * 2016-12-20 2019-08-02 传入制药公司 P2x3拮抗剂的结晶盐和多晶型物
US11414444B2 (en) 2017-11-01 2022-08-16 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
KR20220008286A (ko) * 2019-04-30 2022-01-20 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법
CN113993858A (zh) * 2019-04-30 2022-01-28 北京泰德制药股份有限公司 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途
AU2020265327A1 (en) * 2019-04-30 2021-12-16 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
JP2022535852A (ja) * 2019-06-06 2022-08-10 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
US20030105090A1 (en) * 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
EP2343282B1 (en) * 2004-03-05 2015-07-22 F. Hoffmann-La Roche AG Diaminopyrimidines as P2X3 and P2X2/3 antagonists
AU2006286601B2 (en) * 2005-09-01 2012-07-05 F. Hoffmann-La Roche Ag Diaminopyrimidines as P2X3 and P2X2/3 modulators
CN101300235B (zh) 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
MX2008002731A (es) * 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
EP1924564B1 (en) 2005-09-01 2016-11-09 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2466667T3 (es) * 2006-10-04 2014-06-10 F. Hoffmann-La Roche Ag Proceso para síntesis de derivados de fenoxi diaminopirimidina
WO2008104474A1 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
CN101842359A (zh) * 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
MX367657B (es) * 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
EP3981406A1 (en) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
JP6968810B2 (ja) * 2016-03-14 2021-11-17 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
CA3018180C (en) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor

Also Published As

Publication number Publication date
EP3433258A4 (en) 2019-10-30
US11230532B2 (en) 2022-01-25
RU2018137032A3 (es) 2020-05-22
JP6902045B2 (ja) 2021-07-14
RU2760733C2 (ru) 2021-11-30
WO2017165255A1 (en) 2017-09-28
MA44489A (fr) 2019-01-30
AU2017237929B2 (en) 2021-04-15
JP2019510025A (ja) 2019-04-11
RU2018137032A (ru) 2020-04-27
KR102377805B1 (ko) 2022-03-22
CN108779119A (zh) 2018-11-09
KR20180128015A (ko) 2018-11-30
BR112018069105A2 (pt) 2019-01-29
CA3018180C (en) 2024-02-20
EP3433258A1 (en) 2019-01-30
CN108779119B (zh) 2022-02-08
CA3018180A1 (en) 2017-09-28
EP3433258B1 (en) 2023-07-19
US10662162B2 (en) 2020-05-26
AU2017237929A1 (en) 2018-09-13
US20190055202A1 (en) 2019-02-21
US20200239421A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2018011136A (es) Pirimidinas y variantes de estas, y usos de estas.
MX2018011622A (es) Pirimidinas y sus variantes, y usos de las mismas.
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
CY1124898T1 (el) Παραγωγο πυριμιδινης πυραζολης και χρησεις αυτου
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
ZA201900229B (en) Pyrimidin¿2¿ylamino¿1h¿pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
PH12016500357A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2016000201A (es) Formulaciones de anticuerpos y metodos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CL2012000591A1 (es) Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MY194603A (en) Anti-Complement Factor Bb Antibodies And Uses Thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).